$XBI $89.39 | -1.35%
Pipeline Updates
$CDAK -5.0% Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances. source
$ADPT -5.5% Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease. source
$KDNY +4.8% UPCOMING ENCORE PRESENTATIONS AT ISN WORLD CONGRESS OF NEPHROLOGY 2022. source
$ARWR -2.1% Dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic. source
$IMUX -3.0% will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (IMU-838), the company’s selective oral DHODH inhibitor, at the 17th Congress of European Crohn’s and Colitis Organization (ECCO). source
$CLNN +3.7% will present updated blinded data from its VISIONARY-MS study and results from its REPAIR-MS trial in the stable relapsing MS population at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, taking place from Feb. 24-26, 2022, in West Palm Beach, Fl. source
$MRNA -0.4% Expands Its mRNA Pipeline with Three New Development Programs. source
Business Updates
$ORPH -4.2% Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program. source
$BCRX -2.1% Is implementing an increase in the wholesale acquisition cost (WAC) for ORLADEYO® in the United States from $485,004 on an annual basis ($37,308 per 28-day pack of either 150mg or 110mg capsules) to $499,554.12 on an annual basis ($38,427.24 per 28-day pack of either 150mg or 110mg capsules). source
Posted by DV/FS
Comentarios